The US Food and Drug Administration has approved Johnson & Johnson's Imaavy (nipocalimab) for the treatment of warm autoimmune hemolytic anemia. The. News GxP News.

Johnson & Johnson stock is trading ex-dividend on a $1.34 quarterly payout while record second-quart

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function...

‌Food and ​Drug Administration has approved the ‌expanded ⁠use of ⁠Johnson & Johnson's ​drug ​to ​treat ‌a rare blood disorder, the company ‌said ​on ​Monday. (Reporting ​by ‌Kunal Das and ​Padmanabha...

Healthcare is attracting defensive capital while technology valuations face another violent reset.

Johnson & Johnson (NYSE:JNJ) drew attention as healthcare momentum, oncology strength and a decades-long dividend-raise record kept the franchise in market conversation.

Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI (teclistamab) plus daratumumab as a treatment for adult patients with relapsed or refractory multiple myeloma. The decision extends the approved indication for TECVAYLI in Europe following Phase 3 data that showed significant survival benefits versus standard of care. This expanded label adds a new therapeutic option within Johnson & Johnson's multiple myeloma portfolio and may influence its European oncology...

Johnson & Johnson today announced the publication of the DISH Classification System, a new global consensus framework developed and validated through a clinician-led initiative to standardize how surgical site outcomes are measured and reported and help bring greater visibility to underreported surgical site infections and other wound complications. Published in The British Journal of Surgery, the DISH framework provides a consistent method for identifying and grading four of the most com...

Johnson & Johnson announces the publication of a new global consensus framework for surgical site outcomes.

The approval is based on findings from the ongoing Phase III MajesTEC-3 study involving patients with r/r MM.

Patent expirations are forcing Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) to prove that their newer medicines can replace some of their most successful franchises. Pfizer is simultaneously managing declining COVID-19 revenue and approaching losses of exclusivity, while Johnson & Johnson is already contending with the rapid erosion of Stelara. Their latest results suggest […]

Johnson & Johnson (NYSE:JNJ) has proposed a whopping $5.5 billion settlement to resolve tens of thousands of lawsuits that allege its baby powder and ‌other talc products cause ovarian cancer. The proposed settlement could finally provide investors with the visibility they have lacked for over a decade into one of the company’s largest legal liabilities. […]

Healthcare investors looking for long-term growth don’t always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher’s (NYSE:TMO) […]